Evaluation for the effectiveness and safety for Autologous Bone Marrow Cell infusion (ABMi) therapy for HCV infected liver cirrhosis patient.

Evaluation for the effectiveness and safety for Autologous Bone Marrow Cell infusion (ABMi) therapy for HCV infected liver cirrhosis patient. - ABMi therapy for liver cirrhosis (HCV)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011651

Enrollment

Registered

2013-09-14

Start date

2013-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV infection, Liver cirrhosis

Interventions

Autologous Bone Marrow Cell infusion Standard medical treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Liver cirrhosis related with HCV infection (2) Liver cirrhosis with Child-Pugh Score (over 7) in Child-Pugh B persist for 90 more days, refractory to standard medical treatment (3) >=20 years old and <=75 years old (4) Patient must have signed the consent form

Exclusion criteria

Exclusion criteria: (1) Liver cirrhosis induced by other factor without HCV infection and unknown reasons (2) have a malignant neoplasm, or a history of malignant neoplasm (Including HCC) (3) have risk of Esophageal or/and gastric varices (4) Renal dysfunction with 2mg/dL or higher serum creatinine (5) hemoglobin under 8g/dL or Platelets under 50/mL or Prothrombin activity under 40% (6) Total bilirubin 3.0mg/dL or more (7) Performance Status 3 or 4 (8) Cases that cannot obtain the informed consent to autologous blood transfusion (9) undeniable possibility for HBV infection, HIV infection, ATL infection, human parvovirus B19 infection (10) Pregnancy (11) not fit for general anesthesia (12) have a severe allergic reaction to contrast dye or a history of a severe allergic reaction to contrast dye (13) other conditions that doctor considered not suitable for the study

Design outcomes

Primary

Measure	Time frame
Improvement of Child-Pugh score at 24 weeks after ABMi therapy and control	—

Countries

Japan

Contacts

Public ContactShuji Terai

Yamaguchi University Graduate School of Medicine Department of Gastroenterology & Hepatology

terais@yamaguchi-u.ac.jp0836-22-2241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026